Board approves enabling resolution to explore raising up to Rs. 600 Crores
Orchid Pharma's Board has approved an 'Enabling Resolution' to explore raising funds.
By ScoutQuest · · 2 min read
- Indicative fund raise size
- up to Rs. 600 Crores
- Possible instruments
- equity shares, other eligible securities or instruments including fully or partly convertible debentures
- Board meeting date
- October 20, 2026
Enabling resolution, not an issue yet
- The Board of Directors approved, at its meeting on October 20, 2026, an 'Enabling Resolution' to explore potential market opportunities for raising funds in the best interest of the company.
- The stated ceiling is an indicative amount of up to Rs. 600 Crores (Rupees Six Hundred Crore Only).
- This is a board-level go-ahead to evaluate options. It is not an allotment of shares or securities.
Routes the board may use
- Equity shares or any other eligible securities or instruments, including fully or partly convertible debentures.
- Qualified institutions placement, private placement, public issue of equity shares and/or debt securities, preferential issue, or any other permissible mode.
- Any combination of the above, as considered appropriate.
Approvals involved
- Statutory and regulatory approvals as may be required.
- Approval of the members of the company, wherever applicable, along with other approvals, permissions and consents.
- The update states that the required information is not available as on date.
Why the route matters to a retail holder
- Equity shares or convertible instruments can bring in new shareholders, and convertible debentures can later turn into shares. The effect on the total number of shares depends on the route, the price and the size finally used within the ceiling.
- A preferential issue or a qualified institutions placement typically brings in a set of identified or institutional investors, while a public issue is open more broadly.
- Debt securities, if used, add borrowing rather than new shareholders.
What to track next
- Which route is chosen and the amount raised within the Rs. 600 Crores ceiling.
- Any notice for members' approval, which would carry the price and the number of securities.
- The terms of any convertible instrument, if that route is used.
In short: the board has taken a permission step for a fund raise of up to Rs. 600 Crores and kept the instrument and mode flexible; the actual issue, its size and its terms come later.
Also from Orchid Pharma
Orchid Pharma signs licensing and supply agreement with Libra for Exblifep across nine Latin American markets
24 Oct 2026
Board approves enabling resolution to explore raising up to Rs. 600 crore
20 Oct 2026
Board meeting on October 20, 2026 to consider and evaluate options for raising funds
15 Oct 2026
More numbers
- Indicative amount for fund raising (up to)Rs. 600 Crores
- Aggregate amount up to (Annexure A)Rs. 600 Crores
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.